ClinicalTrials.gg

Program

nirsevimab

Also written as “Nirsevimab”, “MEDI8897” and “MEDI8897 Intravenous”.

Its studies are mostly in Respiratory Syncytial Virus Infections, led by 2 companies.

Furthest: phase 4, since May 21, 201911 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca90 open or runningphase 3since May 21, 2019Apr 3, 2014none ahead
Sanofi21 open or runningphase 4since Jul 31, 2025Jun 24, 2022none ahead

Also a collaborator on its studies: iqvia-rds-inc, iqvia-pty-ltd and iqvia-rds-shanghai-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 3, 2014First study: phase 1 study in Respiratory Syncytial Virus InfectionsNew to AstraZenecaAstraZeneca · NCT02114268 · 342 enrolled · United States
  2. Oct 17, 2014Phase 1 study in Respiratory Syncytial VirusAstraZeneca · NCT02290340 · 151 enrolled · United States, Chile, South Africa
  3. Aug 22, 2016Phase 2 study in Respiratory Syncytial Virus InfectionsAstraZeneca · NCT02878330 · 1,453 enrolled · United States, Argentina, Australia and more
  4. May 21, 20192 phase 3 studies in Respiratory Syncytial Virus InfectionsAstraZeneca · NCT03959488, NCT03979313
  5. Jun 30, 2020Phase 2 study in Respiratory Syncytial Virus InfectionsAstraZeneca · NCT04484935 · 100 enrolled · United States, Belgium, Japan and more
  6. Apr 8, 2021Phase 1 study in Evaluate PK ProfileAstraZeneca · NCT04840849 · 24 enrolled · China
  7. Oct 7, 2021Phase 3 study in Lower Respiratory Tract InfectionAstraZeneca · NCT05110261 · 800 enrolled · China
  8. Jun 24, 2022Sanofi's first study: phase 3 study in RSV ImmunizationNew to SanofiSanofi · NCT05437510 · 8,057 enrolled · France, Germany, United Kingdom
  9. Jul 13, 2023Phase 3 study in Respiratory Syncytial Virus InfectionsAstraZeneca · NCT06042049 · 33 enrolled · Japan
  10. Jul 31, 2025Phase 4 study in RSV ImmunizationSanofi · NCT07109297 · 110 enrolled · India

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Fusion glycoprotein F0 inhibitor”ChEMBL 37, by rule

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07109297RSV Immunization · India4Active, not recruitingSanofiJun 30, 2026110
NCT06042049Respiratory Syncytial Virus Infections · Japan3CompletedAstraZenecaJul 24, 202533
NCT05437510RSV Immunization · France, Germany, United Kingdom3CompletedSanofiMar 27, 20248,057
NCT05110261Lower Respiratory Tract Infection · China3CompletedAstraZenecaNov 24, 2025800
NCT04840849Evaluate PK Profile · China1CompletedAstraZenecaNov 18, 202124
NCT04484935Respiratory Syncytial Virus Infections · United States, Belgium, Japan and more2CompletedAstraZenecaFeb 17, 2023100
NCT03979313Respiratory Syncytial Virus Infections · United States, Argentina, Australia and more3CompletedAstraZenecaMar 11, 20213,012
NCT03959488Respiratory Syncytial Virus Infections · United States, Austria, Belgium and more3CompletedAstraZenecaMay 3, 2021925
NCT02878330Respiratory Syncytial Virus Infections · United States, Argentina, Australia and more2CompletedAstraZenecaJul 17, 20181,453
NCT02290340Respiratory Syncytial Virus · United States, Chile, South Africa1CompletedAstraZenecaSep 28, 2016151
NCT02114268Respiratory Syncytial Virus Infections · United States1CompletedAstraZenecaJun 2015342

How it is read

Names in the registry

  • “Nirsevimab”, 5 entries
  • “MEDI8897”, 3 entries
  • “MEDI8897 Intravenous”, 3 entries
  • “MEDI8897 Intramuscular”, 2 entries
  • “nirsevimab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.